Cargando…

Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?

Inhibitors of fibroblast growth factor receptor (FGFR) signaling have been investigated in various human cancer diseases. Recently, the first compounds received FDA approval in biomarker-selected patient populations. Different approaches and technologies have been applied in clinical trials, ranging...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ellinghaus, Peter, Neureiter, Daniel, Nogai, Hendrik, Stintzing, Sebastian, Ocker, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563413/ https://www.ncbi.nlm.nih.gov/pubmed/36231142 http://dx.doi.org/10.3390/cells11193180

Ejemplares similares

Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future
por: Ocker, Matthias, et al.
Publicado: (2021)

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
por: Stintzing, Sebastian, et al.
Publicado: (2011)

Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets
por: Neureiter, Daniel, et al.
Publicado: (2019)

Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation
por: Bekric, Dino, et al.
Publicado: (2022)

Many Paths to the Same Goal: Balancing Exploration and Exploitation during Probabilistic Route Planning
por: Jackson, Brian J., et al.
Publicado: (2020)

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
por: Grünewald, Sylvia, et al.
Publicado: (2019)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
por: Tao, Zhanchao, et al.
Publicado: (2022)

Editorial: Novel therapeutic approaches for biliary tract cancer and hepatocellular carcinoma
por: Bekric, Dino, et al.
Publicado: (2023)

Expression Atlas of FGF and FGFR Genes in Pancancer Uncovered Predictive Biomarkers for Clinical Trials of Selective FGFR Inhibitors
por: Li, Yuan, et al.
Publicado: (2020)

Radiosensitization by the Selective Pan-FGFR Inhibitor LY2874455
por: Darwis, Narisa Dewi Maulany, et al.
Publicado: (2022)

Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
por: Lima, Nadia Carvalho, et al.
Publicado: (2020)

Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines
por: Zopf, Steffen, et al.
Publicado: (2012)

Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors
por: Qu, Lingzhi, et al.
Publicado: (2022)

ASP5878, a selective FGFR inhibitor, to treat FGFR3‐dependent urothelial cancer with or without chemoresistance
por: Kikuchi, Aya, et al.
Publicado: (2017)

Many paths to COVID-19 lymphocyte dysfunction
por: Hegde, Samarth
Publicado: (2020)

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
por: Subbiah, Vivek, et al.
Publicado: (2023)

Mother and Daughter Carrying of the Same Pathogenic Variant in FGFR2 with Discordant Phenotype
por: Lo Vecchio, Filomena, et al.
Publicado: (2022)

Biliary tract cancer stem cells - translational options and challenges
por: Mayr, Christian, et al.
Publicado: (2017)

SUN-087 FGFR-Selective Tyrosine Kinase Inhibitors, Such as Infigratinib, Show Potency and Selectivity for FGFR3 at Pharmacologically Relevant Doses for the Potential Treatment of Achondroplasia
por: Dobscha, Katherine, et al.
Publicado: (2020)

Paths: why is life ﬁlled with so many detours?
por: Gulyás, András, et al.
Publicado: (2021)

Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy
por: Kim, S-M, et al.
Publicado: (2016)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

A Simple Histone Code Opens Many Paths to Epigenetics
por: Sneppen, Kim, et al.
Publicado: (2012)

Cancer immunotherapy with γδ T cells: many paths ahead of us
por: Kabelitz, Dieter, et al.
Publicado: (2020)

The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells
por: Mayr, Christian, et al.
Publicado: (2015)

How Many Thymocytes Audition for Selection?
por: Merkenschlager, Matthias, et al.
Publicado: (1997)

bcl-2-specific siRNAs restore Gemcitabine sensitivity in human pancreatic cancer cells
por: Okamoto, Kinya, et al.
Publicado: (2007)

The Crosstalk of miRNA and Oxidative Stress in the Liver: From Physiology to Pathology and Clinical Implications
por: Klieser, Eckhard, et al.
Publicado: (2019)

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021)

IRE1α Stands astride Many Paths to Insulin Production
por: Sedwick, Caitlin
Publicado: (2015)

Early Steps in the Value of Cancer Care—Many Paths Remain Unexplored
por: Goldstein, Daniel A., et al.
Publicado: (2018)

Correction to: Cancer immunotherapy with γδ T cells: many paths ahead of us
por: Kabelitz, Dieter, et al.
Publicado: (2020)

Commentary: All roads lead to Rome? The many paths to cardiothoracic surgery
por: Ghanta, Ravi K., et al.
Publicado: (2021)

Bcl‐2 inhibitors enhance FGFR inhibitor‐induced mitochondrial‐dependent cell death in FGFR2‐mutant endometrial cancer
por: Packer, Leisl M., et al.
Publicado: (2019)

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models
por: Zhang, H, et al.
Publicado: (2014)

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment
por: Cowell, John K., et al.
Publicado: (2021)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

Different Paths, Same Structure: “Developmental Systems Drift” at Work
por: Robinson, Richard
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_h0evd1a3kb48n65aalebadmpk4